Oligonucleotide & Peptide Therapeutics is a 4-day webcast series dedicated to oligonucleotide and
peptide,
covering the entire spectrum of oligonucleotides, peptides, mRNA, and genome editing in early discovery to
late-stage development and commercialization.
The Digital Week event program offers free registration for your prospects to watch sessions,
access video and
white paper content, and interact with the community through live polling and Q&As. From September
19th-22nd, we hope you will join GenScript and our presentation on mRNA-based therapeutics
development as we continue to celebrate our community and the advancement of drug discovery and biotechnology
innovation.
Topic: Critical Attributes of mRNA manufacturing for early phase therapeutics development
Date: September 19, 2022
Time: 10 AM EDT
Speaker: Dr. Fengmei Pi, Head of RNA Biology Department,
GenScript
Presentation Information
RNA-based therapeutics are becoming the third milestone in human drug development history,
following chemical
drugs and protein-based drugs. Platform development for preparing mRNA by in vitro transcription further speeds
up this process. Improving the critical quality attributes of mRNA molecules could impact their expression and
therapeutic efficiency. These CQAs for mRNA include: the integrity of mRNA; the yield of IVT reactions; polyA
tail length and distribution; impurity dsRNA; impurity plasmid DNA; and free cap analogue residue levels. To
improve mRNA integrity, in addition to optimizing IVT conditions, linear plasmid quality is also important. I
will discuss how these factors affect mRNA quality and our progress in controlling these parameters in the mRNA
manufacturing process for early-stage mRNA therapeutic development.
Most Popular Products
CRISPR Gene Editing
Antibodies
Protein Electrophoresis and Blotting
Molecular Biology
Stable Cell Lines
Cell Therapy
Diagnostics
Resources
